Medidata Solutions, a global leader in electronic data capture
(EDC), management and reporting solutions, today announced that Vice
President of Global Regulatory Affairs and Quality Assurance Earl
Hulihan has been selected to receive the Drug Information
Association's (DIA) Founders Service Award. This award recognizes
individuals who have advanced the mission, vision and values of DIA
and fostered the growth and development of the organization through
their sustained dedication, time and effort.
DIA's highest honor for volunteerism, the Founders Service Award
honors Hulihan's lifelong contributions to medicine, regulatory
science and people around the world throughout his distinguished
career. Hulihan has helped the industry make significant strides in
quality assurance, regulatory compliance, drug development and
clinical research since the early 1970s. As the current Vice President
of Global Regulatory Affairs and Quality Assurance at Medidata
Solutions, Hulihan is responsible for maintaining the highest
standards for all Medidata products and services, and ensuring
compliance with the US and international clinical and quality
regulations.
Outside of the professional environment, Hulihan has provided
advice and training to regulatory agency personnel within the U.S.
FDA, European and Asian communities and has more than 15 years of
experience in clinical medicine as a research specialist, teaching
specialist, clinical physiologist and clinical investigator. Hulihan
has been involved with DIA for over 30 years and is a frequent
contributor to seminars, training and events and serves as global
chair of the Validation SIAC/Community and vice-chair of the DIA
Advisory Council for North America. He has been very active in the
most recent launch of DIA initiatives within the India and China
regions.
"DIA has always been one of the most influential associations and
driving forces in the industry, and I am honored to have been able to
contribute to the organization over the years," said Hulihan.
"Medidata Solutions consistently maintains a strong presence at DIA
conferences and events, and I look forward to continuing to drive
critical discussions and foster commitment to the DIA community."
Prior to joining Medidata, Hulihan served as senior vice president
of regulatory consulting services at META Solutions Inc. and vice
president of quality systems at EduQuest where he provided regulatory
consulting, auditing and training services to the global
pharmaceutical, biologics and medical device industries. Hulihan has
held a variety of other senior management positions in the global
pharmaceutical environment serving both pharmaceutical companies and
CROs, and has been involved in research across the globe.
"Earl has shown an unmatched dedication to advancing the life
sciences industry through his commitment to the DIA community
throughout his career," said Tarek Sherif, CEO of Medidata Solutions.
"As one of the most sought after thought-leaders within Medidata and
the industry at large, Earl continues to make vital contributions to
his peers and colleagues that have helped drive significant
developments and shape the future of the clinical world."
The DIA Founders Service Award will be presented publicly during
the DIA Annual Meeting at the Georgia World Congress Center (GWCC) in
Atlanta, Georgia at 8:30 a.m. on June 18, 2007.
About Medidata Solutions Worldwide
Medidata Solutions helps the world's leading pharmaceutical,
biotechnology, medical device and research organizations maximize the
value of their clinical research investments. Innovative process
design, technology and services streamline clinical trials by
providing early visibility to reliable clinical data - the lifeblood
of every research organization. Working with companies and
institutions both large and small, Medidata Solutions helps clinical
researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80
countries. Medidata Solutions brings significant value to its broad
client base with deep clinical experience and expertise in more than
20 therapeutic areas, projects in Phase I, II, III, IV, registries and
surveillance, and studies with thousands of investigators and
tens-of-thousands of subjects. For more information, please visit
www.mdsol.com.